慢性乙型肝炎患者抗病毒疗效预测指标的研究进展

鲍腾; 陶奔; 郜玉峰

doi:10.3969/j.issn.1001-5256.2017.10.032

慢性乙型肝炎患者抗病毒疗效预测指标的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.10.032

安徽医科大学第二附属医院肝病科

基金项目:

安徽省自然科学基金(1608085MH164)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1545
- HTML全文浏览量: 48
- PDF下载量: 373
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-02
- 出版日期: 2017-10-20

Research advances in predictive indices for antiviral effect in patients with chronic hepatitis B

Department of Hepatology, The Second Affiliated Hospital of Anhui Medical University

Research funding:

摘要

摘要: 如何优化慢性乙型肝炎患者的抗病毒疗效一直是临床研究的热点,近年来关于疗效预测的研究逐渐增加,主要包括HBs Ag、抗-HBc、ccc DNA、乙型肝炎病毒核心相关抗原和HBV RNA定量对临床疗效的预测研究,对这些指标的预测效果进行了综述。
- 肝炎,乙型,慢性 /
- 抗病毒药 /
- 治疗结果 /
- 综述
Abstract: Optimization of antiviral effect in patients with chronic hepatitis B has always been a hot topic of clinical research. In recent years, more and more studies have focused on the prediction of antiviral effect, including the values of HBs Ag, anti-HBc, covalently closed circular DNA, HBcr Ag, and HBV RNA quantitation in predicting antiviral effect. This article reviews the predictive values of these markers.
- hepatitis B, chronic /
- antiviral agents /
- treatment outcome /
- review

HTML全文

参考文献(30)

[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[2]SETO WK, HUI AJ, WONG VW, et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B:a multicentre prospective study[J].Gut, 2015, 64 (4) :667-672.

[3]ZHAO SQ, YANG XW, LIU B, et al.Analysis of clinical characteristics between HBe Ag-negative and HBe Ag-positive patients with chronic hepatitis B[J].Int J Virol, 2016, 23 (1) :29-31. (in Chinese) 赵树巧, 杨宪武, 刘冰, 等.HBe Ag阴性与阳性慢性乙型肝炎患者的临床特征对比分析[J].国际病毒学杂志, 2016, 23 (1) :29-31.

[4]LI WJ, LI BA, ZHAO JM, et al.Quantitative analyses of intrahepatic HBV ccc DNA and serum HBs Ag in 54 patients with chronic hepatitis B[J].Chin J Hepatol, 2011, 19 (11) :815-817. (in Chinese) 李韦杰, 李伯安, 赵景民, 等.54例慢性乙型肝炎患者肝组织乙型肝炎病毒共价闭合环状DNA与血清HBs Ag定量检测结果分析[J].中华肝脏病杂志, 2011, 19 (11) :815-817.

[5]NIU ZL, ZHU X, SHEN WQ, et al.Study on influence of interferon on changes of HBV ccc DNA in hepatocytes and serum HBs Ag and HBV DNA of patients with chronic hepatitis B[J].Chin JNosocomio, 2014, 24 (4) :792-795. (in Chinese) 钮志林, 朱翔, 沈伟强, 等.干扰素对慢性乙型肝炎患者肝细胞内HBV ccc DNA、血清HBs Ag、HBV DNA的影响研究[J].中华医院感染学杂志, 2014, 24 (4) :792-795.

[6]LI W, ZHAO J, ZOU Z, et al.Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection[J].PLo S One, 2014, 9 (2) :e89046.

[7]SONNEVELD MJ, RIJCKBORST V, BOUCHER CA, et al.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline[J].Hepatology, 2010, 52:1251-1257.

[8]CHEN CH, LU SN, HUNG CH, et al.The role of hepatitis B surface antigen quantification in predicting HBs Ag loss and HBV relapse after discontinuation of lamivudine treatment[J].J Hepatol, 2014, 61 (3) :515-522.

[9]QIU YW, HUANG LH, YANG WL, et al.Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients[J].Int J Infect Dis, 2016, 43:43-48.

[10]HOSAKA T, SUZUKI F, KOBAYSHI M, et al.Clearance of hepatitis B surface antigen during long-term nucleot (s) ide analog treatment in chronic hepatitis B:results from a nine-year longitudinal study[J].J Gastroenterol, 2013, 48:930-941.

[11]CAI W, XIE Q, AN B, et al.On-treatment serum HBs Ag level is predictive of sustained off-treatment virologic response to telbivudine in HBe Ag-positive chronic hepatitis B patients[J].J Clin Virol, 2010, 48 (1) :22-69.

[12]ZHANG N, YAN XB, HAO JG, et al.Changes and clinical significance of quantitative hepatitis B surface antigen in patients with chronic hepatitis B receiving interferon therapy[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2016, 10 (2) :146-150. (in Chinese) 张楠, 颜学兵, 郝俊贵, 等.HBs Ag定量在慢性乙型肝炎患者干扰素抗病毒治疗中的变化及临床意义[J/CD].中华实验和临床感染病杂志:电子版, 2016, 10 (2) :146-150.

[13]PIRATVISUTH T, MARCELLIN P, POPESCU M, et al.Hepatitis B surface antigen:association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients[J].Hepatol Int, 2013, 7 (2) :429-436.

[14]NING Q, HAN M, SUN Y, et al.Switching from entecavir to Peg IFN alfa-2a in patients with HBe Ag-positive chronic hepatitis B:a randomised open-label trial (OSST trial) [J].J Hepatol, 2014, 61 (4) :777-784.

[15]SONG LW, LIU PG, LIU CJ, et al.Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection[J].Clin Microbiol Infect, 2015, 21 (2) :197-203.

[16]YUAN Q, SONG LW, LIU CJ, et al.Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients[J].Gut, 2013, 62 (1) :182-184.

[17]HOU FQ, SONG LW, YUAN Q, et al.Quantitative hepatitis Bcore antibody level is a new predictor for treatment response in HBe Ag positive chronic hepatitis B patients receiving peginterferon[J].Theranostics, 2015, 5 (3) :218-226.

[18]FAN R, SUN J, YUAN Q, et al.Baseline quantitative hepatitis Bcore antibody titre alone strongly predicts HBe Ag seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos (t) ide analogues[J].Gut, 2016, 65 (2) :313-320.

[19]LU HY, ZHUANG LW, YU YY, et al.Effects of antiviral agents on intrahepatic ccc DNA in HBe Ag-positive chronic hepatitis B[J].Chin J Hepatol, 2008, 16 (3) :198-202. (in Chinese) 陆海英, 庄立伟, 于岩岩, 等.抗病毒药物对肝组织乙型肝炎病毒共价闭合环状DNA的影响[J].中华肝脏病杂志, 2008, 16 (3) :198-202.

[20]WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, et al.Persistence of ccc DNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J].Gastroenterology, 2004, 126 (7) :1750-1758.

[21]LARAS A, KOSKINAS J, DIMOU E, et al.Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients[J].Hepatology, 2006, 44 (3) :694-702.

[22]ZHONG Y, HAN J, ZOU Z, et al.Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with realtime PCR[J].Clin Chim Acta, 2011, 412 (21-22) :1905-1911.

[23]KIMURA TA, ROKUHARA Y, SAKAMOTO S, et al.Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load[J].J Clin Microbiol, 2002, 40 (2) :439-445.

[24]MATSUMOTO A, TANAKA E, SUZUKI Y, et al.Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos (t) ide analogs in patients with chronic hepatitis B[J].Hepatol Res, 2012, 42 (2) :139-149.

[25]CHUAYPEN N, POSUWAN N, PAYUNGPORN S, et al.Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBe Ag-positive chronic hepatitis B[J].Liver Int, 2016, 36 (6) :827-836.

[26]MA H, YANG RF, LI XH, et al.HBcr Ag identifies patients failing to achieve HBe Ag seroconversion treated with pegylated interferon alfa 2b[J].Chin Med J, 2016, 129:2212-2219.

[27]HUANG YW, CHAYAMA K, TSUGE M.Different effects of interferon and lamivudine on serum HBV DNA inhibition in patients with chronic hepatitis B[J].Antiviral therapy, 2010, 15:177-184.

[28]JANSEN L, KOOTSTRA NA, VANDORT KA, et al.Hepatitis BVirus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos (t) ide analogues[J].J Infect Dis, 2016, 213 (2) :224-232.

[29]HATAKEYAMA T, NOGUCHI C, HIRAGA N, et al.Serum HBVRNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine[J].Hepatology, 2007, 45 (5) :1179-1186.

[30]van BMMEL F, BARTENS A, MYSICKOVA A, et al.Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J].Hepatology, 2015, 61 (1) :66-76.

施引文献

资源附件(0)

访问统计